نتائج البحث

Immunotherapy combined with antiangiogenic therapy as third- or further-line therapy for stage IV non-small cell lung cancer patients with ECOG performance status 2: A retrospective study.

• Authors : Li S; Department of Oncology, Binzhou Medical University Hospital, Binzhou, Shandong, People's Republic of China.; Yu ZS

Subjects: Angiogenesis Inhibitors*/Angiogenesis Inhibitors*/Angiogenesis Inhibitors*/therapeutic use ; Angiogenesis Inhibitors*/Angiogenesis Inhibitors*/Angiogenesis Inhibitors*/adverse effects ; Antineoplastic Combined Chemotherapy Protocols*/Antineoplastic Combined Chemotherapy Protocols*/Antineoplastic Combined Chemotherapy Protocols*/therapeutic use

• Source: Cancer medicine [Cancer Med] 2024 Jun; Vol. 13 (11), pp. e7349.Publisher: John Wiley & Sons Ltd Country of Publication: United States NLM ID: 101595310 Publication Model: Print Cited Medium: Internet ISSN:

تفاصيل العنوان

Predicting survival in metastatic non-small cell lung cancer patients with poor ECOG-PS: A single-arm prospective study.

• Authors : Cunha MT; Serviço de Oncologia Clínica, Instituto do Câncer do Estado de São Paulo, Hospital das Clínicas HCFMUSP, Faculdade de Medicina, Universidade de São Paulo, São Paulo, Brazil.; de Souza Borges AP

Subjects: Carcinoma, Non-Small-Cell Lung*/Carcinoma, Non-Small-Cell Lung*/Carcinoma, Non-Small-Cell Lung*/pathology ; Lung Neoplasms*/Lung Neoplasms*/Lung Neoplasms*/pathology; Humans

• Source: Cancer medicine [Cancer Med] 2023 Feb; Vol. 12 (4), pp. 5099-5109. Date of Electronic Publication: 2022 Sep 26.Publisher: John Wiley & Sons Ltd Country of Publication: United States NLM ID: 101595310 Publication Model: Print-Electronic Cited Medium: Internet

تفاصيل العنوان

Study of Pembrolizumab and Single Agent Chemotherapy as First Line Treatment for Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer With Eastern Cooperative Oncology Group (ECOG) Performance Status of 2

• Authors : Megan Baumgart, Assistant Professor

• Source: A Pilot Study of Pembrolizumab and Single Agent Chemotherapy as First Line Treatment for Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer With Eastern Cooperative Oncology Group

تفاصيل العنوان

Pemetrexed Disodium in Treating Patients With Stage IV Non-small Cell Lung Cancer and ECOG Performance Status 3

• Authors : National Cancer Institute (NCI)

• Source: A Pilot Study Evaluating Pemetrexed in ECOG Performance Status 3 Patients With Stage IV Non-squamous Non-small Cell Lung Cancer

تفاصيل العنوان

Efficacy and safety of concurrent chemoradiotherapy in ECOG 2 patients with locally advanced non-small-cell lung cancer: a subgroup analysis of a randomized phase III trial.

• Authors : Bi N; Department of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, No. 17 Panjiayuannanli, Chaoyang District, Beijing, 100021, China.; Liu L

Subjects: Antineoplastic Combined Chemotherapy Protocols/Antineoplastic Combined Chemotherapy Protocols/Antineoplastic Combined Chemotherapy Protocols/*therapeutic use ; Carcinoma, Non-Small-Cell Lung/Carcinoma, Non-Small-Cell Lung/Carcinoma, Non-Small-Cell Lung/*therapy ; Chemoradiotherapy/Chemoradiotherapy/Chemoradiotherapy/*mortality

• Source: BMC cancer [BMC Cancer] 2020 Apr 06; Vol. 20 (1), pp. 278. Date of Electronic Publication: 2020 Apr 06.Publisher: BioMed Central Country of Publication: England NLM ID: 100967800 Publication Model: Electronic Cited Medium: Internet ISSN: 1471-2407

تفاصيل العنوان

Patient-reported tolerability of veliparib combined with cisplatin and etoposide for treatment of extensive stage small cell lung cancer: Neurotoxicity and adherence data from the ECOG ACRIN cancer research group E2511 phase II randomized trial.

• Authors : Steffen McLouth LE; Department of Behavioral Science, Center for Health Equity Transformation, University of Kentucky College of Medicine, Lexington, KY, USA.; Zhao F

Subjects: Antineoplastic Combined Chemotherapy Protocols/Antineoplastic Combined Chemotherapy Protocols/Antineoplastic Combined Chemotherapy Protocols/*therapeutic use ; Lung Neoplasms/Lung Neoplasms/Lung Neoplasms/*drug therapy ; Lung Neoplasms/Lung Neoplasms/Lung Neoplasms/*pathology JET protocol

• Source: Cancer medicine [Cancer Med] 2020 Oct; Vol. 9 (20), pp. 7511-7523. Date of Electronic Publication: 2020 Aug 28.Publisher: John Wiley & Sons Ltd Country of Publication: United States NLM ID: 101595310 Publication Model: Print-Electronic Cited Medium: Internet

تفاصيل العنوان

Erlotinib, cabozantinib, or erlotinib plus cabozantinib as second-line or third-line treatment of patients with EGFR wild-type advanced non-small-cell lung cancer (ECOG-ACRIN 1512): a randomised, controlled, open-label, multicentre, phase 2 trial

• Authors : Neal, Joel W; Dahlberg, Suzanne E; Wakelee, Heather A

Subjects: Biomedical and Clinical Sciences; Clinical Sciences; Oncology and Carcinogenesis

• Source: The Lancet Oncology. 17(12)

تفاصيل العنوان

Multicenter randomized, open-label phase II trial of sequential erlotinib and gemcitabine compared with gemcitabine monotherapy as first-line therapy in elderly or ECOG PS two patients with advanced NSCLC.

• Authors : Michael M; Division of Cancer Medicine, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.; White SC

Subjects: Adenocarcinoma/Adenocarcinoma/Adenocarcinoma/*drug therapy ; Antineoplastic Combined Chemotherapy Protocols/Antineoplastic Combined Chemotherapy Protocols/Antineoplastic Combined Chemotherapy Protocols/*therapeutic use ; Carcinoma, Large Cell/Carcinoma, Large Cell/Carcinoma, Large Cell/*drug therapy

• Source: Asia-Pacific journal of clinical oncology [Asia Pac J Clin Oncol] 2015 Mar; Vol. 11 (1), pp. 4-14. Date of Electronic Publication: 2014 Feb 27.Publisher: Blackwell Pub. Asia Country of Publication: Australia NLM ID: 101241430 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

تفاصيل العنوان

Comparison of an inflammation-based prognostic score (GPS) with performance status (ECOG) in patients receiving platinum-based chemotherapy for inoperable non-small-cell lung cancer.

• Authors : Forrest LM; University Department of Surgery, Royal Infirmary, Glasgow G31 2ER, Scotland, UK.; McMillan DC

Subjects: Antineoplastic Agents/Antineoplastic Agents/Antineoplastic Agents/*therapeutic use ; Biomarkers, Tumor/Biomarkers, Tumor/Biomarkers, Tumor/*blood ; Carcinoma, Non-Small-Cell Lung/Carcinoma, Non-Small-Cell Lung/Carcinoma, Non-Small-Cell Lung/*mortality

• Source: British journal of cancer [Br J Cancer] 2004 May 04; Vol. 90 (9), pp. 1704-6.Publisher: Nature Publishing Group on behalf of Cancer Research UK Country of Publication: England NLM ID: 0370635 Publication Model: Print Cited Medium:

تفاصيل العنوان

Prospective Non-Interventional Study Comparing Osimertinib +/- Chemotherapy for EGFR-Mutated NSCLC Patients

• Authors : ECOG-ACRIN Cancer Research Group

• Source: Prospective Non-Interventional Study Comparing Standard of Care Osimertinib +/- Chemotherapy for EGFR-Mutated Non-Small Cell Lung Cancer (NSCLC) Patients

تفاصيل العنوان